The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Clinical developments | 631 |
| Other segments expenses | 648 |
| Net loss | -1,279 |
| Share-based compensation | 245 |
| Related parties | 818 |
| Other accounts payables and accrued expenses | 6 |
| Net cash used in operating activities | -210 |
| Receipt of a loan | -7 |
| Proceeds from issuance of common stock and warrants | 243 |
| Net cash provided by financing activities | 236 |
| Change in cash and cash equivalents | 26 |
| Cash and cash equivalents at the beginning of the year | 19 |
| Cash and cash equivalents at the end of the year | 45 |
Raphael Pharmaceutical Inc. (RAPH)
Raphael Pharmaceutical Inc. (RAPH)